ClinicalTrials.gg
TerminatedNCT05209737TrendUpdated Apr 15, 2026

Trendelenburg as a First-line Intervention in Critically Ill, Sedated, Invasively Mechanically Ventilated, Hypotensive Patients

An interventional study of Trendelenburg position and Semirecumbent position in Hypotension and Shock, sponsored by Negovsky Reanimatology Research Institute. Terminated at 2 sites in Russia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-15.

Sponsored by Negovsky Reanimatology Research Institute · Not applicable, Interventional, and Treatment

How we know

Why this study was terminated
Recruiting problems

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

A pilot randomized controlled trial to evaluate the efficacy and safety of Trendelenburg position in critically ill patients with hypotension, mainly patients with septic shock and post operative vasoplegia. The main aim is to assess whether Trendelenburg position can improve organ function through a reduction in the need of fluid infusion and dose of vasopressors.

Patients will be screened for participation in the study and eventually randomized based on a balanced randomization scheme (1:1) to Trendelenburg position up to 72 hours after intensive care unit (ICU) admission or Semirecumbent position (standard of care).

Read the detailed description

Current consensus on circulatory shock management defines shock as a life-threatening, generalized form of acute circulatory failure associated with inadequate tissue perfusion. Recommended interventions to improve perfusion include early hemodynamic stabilization through fluid resuscitation, along with treatment of the cause of shock. If impaired cardiac function results in inadequate cardiac output and tissue hypoperfusion despite fluid therapy, vasopressor agents should be administered.

Nevertheless, fluid overload causes multi-organ edema, such as pulmonary edema or hepatic congestion. Moreover, the negative effects of fluid intravenous administrations were also studied on healthy volunteers during the years. Most of them showed the development of lung injury due to fluid administration.

In addition, vasopressors are also associated with poor outcomes. Described serious adverse effects include organ ischemia, tachyarrhythmias, and atrial fibrillation, leading to organ dysfunction and mortality.

The head-down position, also known as the Trendelenburg position, was originally used by the surgeon Friederich Trendelenburg to improve surgical exposure of pelvic organs. The Trendelenburg position became then a widely popular procedure in managing patients with hypotension and shock. The primary effect of the Trendelenburg position is an increase in cardiac output. Although the short term effect on blood pressure and CO is certain, there is no agreement on its benefit in terms of tissue perfusion and clinical outcome in critically ill hypotensive patients, as nobody has attempted the Trendelenburg position as first line management.

To date, the gold standard position for patients in ICU according to the latest ESICM guidelines to prevent ventilator-associated pneumonia is the semirecumbent position. Experts recommend elevating the head of the patient on the bed to a 20-45 degrees position, preferably >30 degrees position.

Critically ill patients with hypotension, mainly patients with septic shock and those with post-operative vasoplegia, may be a subgroup of patients, who would benefit from a head-down position if the risks of aspiration pneumonia are minimized. The Trendelenburg position might permit to avoid the deleterious side effects of fluids and vasoconstrictor administration.

The idea is that Trendelenburg position can improve organ function through a reduction in the need of fluid infusion and doses of vasopressors in hypovolemic, hypotensive ICU patients and therefore increase ventilator free days.

The main aim of this trial is to assess if Trendelenburg position can reduce time to severe hypotension resolution.

02

Conditions studied

  • Hypotension
  • Shock

Browse trials for

Keywords

  • Trendelenburg position
  • hypotension
  • hypovolemic shock
  • shock
  • head-down position
03

In context

Hypotension

892 studies on the registry are indexed under Hypotension; 199 are open to participants now.

This study's enrollment of 10 is below the median of 86 across 593 interventional studies indexed under Hypotension.

Browse Hypotension studies →

Lead sponsor

Negovsky Reanimatology Research Institute is the lead sponsor of 10 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age >18 years
  • Admitted to the intensive care unit (ICU);
  • Invasive mechanical ventilation;
  • Pharmacological sedation;
  • Mean arterial pressure (MAP)\<65 mmHg or need of fluids infusion or any vasopressor in order to keep MAP > 65 mmHg
  • Ongoing invasive and/or non-invasive arterial blood pressure monitoring
  • Central venous line with central venous pressure (CVP) monitoring
  • Naso-gastric tube in situ
  • Indwelling bladder catheter
  • Consent according to local ethical committee rules

Exclusion criteria

Exclusion Criteria:

  • > 45
  • Documented or suspected increased intracranial pressure, based on medical history or actual clinical condition (es. intracranial tumor, cerebral hemorrhage, encephalitis,...);
  • Intra-abdominal hypertension >25 mmHg
  • Documented or suspected increased intraocular pressure (any degree of glaucoma)
  • Full stomach pyloric incontinence;
  • Gastric stasis, defined as aspiration from the NG (nasogastric) tube of fecal, bloody, or green fluid greater than 100 mL upon insertion of the tube or within the preceding hour;
  • Ongoing enteral nutrition
  • No central line inserted or femoral central line only
  • Not sutured known diaphragm lesions
  • Known hiatus hernia
  • Aortic bifurcation and/or lower extremity arterial stenosis ≥70% combined with stage 3 intermittent claudication (pain at rest)
  • Patients who are not able to be investigated with a leg raising test (eg lower extremities fractures, backbone fractures or backbone pain or deformity, and those patients with large cannulas in the femoral vessels)
  • Demand of specific postures (eg Trauma, fractures, backbone pain or deformity, patients with large cannulas in the femoral vessels, pronation including first pronation planned within 6 h…)
  • Any device which, according to the clinician, makes it unfeasible or unsafe to put patients in the Trendelenburg position (eg Drainage in thoracic cavity)
  • Mechanical Circulatory Support;
  • (CHD) (Gleen, Fontaine);
  • Advanced right ventricular dysfunction or advanced cardiac failure, in which volume overload worsens cardiac function (plateau stage in the Frank-Starling curve);
  • Actual upper gastrointestinal bleeding
  • Passive leg raising test non-responder
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    Trendelenburg position

    Position: 10-degree Head-down position

    Procedure: Trendelenburg position

  • Active comparator
    Semirecumbent position

    Position: 30-degree Head-up position

    Procedure: Semirecumbent position

Interventions

  • ProcedureTrendelenburg position

    A 10-degree head-down position will be used in this group

  • ProcedureSemirecumbent position

    A 30-degree head-up position will be used in this group

06

What researchers measure

Primary outcomes

  1. Time to severe hypotension resolution

    Time from randomization to timepoint in which MAP \> 65 mmHg not requiring fluids or vasoactive drugs (VIS \< 5), lasting \> 1 hour, in the semirecumbent position

    Time frame: 72 hours

Secondary outcomes

  1. Ventilator-free days at 28 days

    28 days - number of days in which the mechanical lung ventilation was not used

    Time frame: 28 days

  2. ICU-free days at 28 days

    28 days - number of days in which the patient was not in an intensive care unit

    Time frame: 28 days

  3. Restarting vasopressor/inotrope therapy

    Using vasopressors and/or inotropes to maintain MAP ≥ 65 mm Hg after premature study termination (Vasoactive inotrope score \> 5)

    Time frame: 28 days

  4. 28-days mortality

    all cause mortality

    Time frame: 28 days

  5. 90-days mortality

    all cause mortality

    Time frame: 90 days

  6. Acute kidney injury

    number of patients who have acute kidney injury according to KDIGO classification

    Time frame: 28 days

  7. Acute liver failure

    Rapid hepatic injury with coagulation derangements and hepatic encephalopathy and multi-organ failure in a patient with no history of liver disease

    Time frame: 28 days

  8. Ventilation-associated pneumonia

    Pneumonia due to mechanical lung ventilation

    Time frame: 28 days

07

Study locations

2 sites
  • Vishnevsky Center of Surgery
    Moscow, 117997, Russia
  • Demikhov Municipal Clinical Hospital 68
    Moscow, Russia
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2022 to primary completion in Oct 2025, 44 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 13, 2022
First posted
Jan 27, 2022
StartActual
Jan 31, 2022
Primary completionActual
Oct 20, 2025
CompletionActual
Nov 20, 2025
Last update
Apr 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05209737
Lead sponsor
Negovsky Reanimatology Research Institute
Responsible party
Valery Likhvantsev, MD (Head of the Research V. Negovsky Reanimatology Research Institute, Negovsky Reanimatology Research Institute) — Principal investigator
First posted
Jan 27, 2022
Start date
Jan 31, 2022
Primary completion
Oct 20, 2025
Completion
Nov 20, 2025
Last update
Apr 15, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion